TG THERAPEUTICS, INC. (TGTX) Return on equity 2016–2025
TG THERAPEUTICS, INC. (TGTX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
69.0%FY2025 · since FY2016: -218.2% → 69.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 69.0% | +58.5 pp |
| FY2024 | 10.5% | +2.6 pp |
| FY2023 | 7.9% | +389.9 pp |
| FY2022 | -382.0% | -235.2 pp |
| FY2021 | -146.8% | -93.0 pp |
| FY2020 | -53.8% | +393.9 pp |
| FY2019 | -447.7% | +274.1 pp |
| FY2018 | -721.8% | -544.9 pp |
| FY2017 | -176.8% | +41.3 pp |
| FY2016 | -218.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More TGTX financial trends
TGTX RevenueTGTX Net incomeTGTX Net marginTGTX Gross profitTGTX Gross marginTGTX Operating incomeTGTX Operating marginTGTX Operating cash flowTGTX Free cash flowTGTX Capital expendituresTGTX Stock buybacksTGTX Dividends paidTGTX Total assetsTGTX Total liabilitiesTGTX Shareholders’ equityTGTX overview →